Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01702649 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects
A Phase 1 study of Healthy Volunteers and Bacterial Infections, sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company).
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT01702649 is a Phase 1 study of Healthy Volunteers and Bacterial Infections that has completed, run by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company). The registered enrollment target is 36 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01702649, a Phase 1 study of Healthy Volunteers and Bacterial Infections, has completed, sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
RPX2003 (biapenem) is being studied in combination with a beta-lactamase inhibitor to treat bacterial infections, including those due to multi-drug resistant bacteria.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RPX2003 (Biapenem)
Study Locations (1)
Arizona
- Celerion - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-08 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01702649
The ClinicalTrials.gov registry entry for NCT01702649 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (93% lower). The listed sponsor is Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company), which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01702649 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT01702649 about?
NCT01702649 is a clinical study titled "Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects". RPX2003 (biapenem) is being studied in combination with a beta-lactamase inhibitor to treat bacterial infections, including those due to multi-drug resistant bacteria.
What is the current status of trial NCT01702649?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2012-08. Estimated completion is 2012-11.
What conditions does trial NCT01702649 study?
This clinical trial studies the following conditions: Healthy Volunteers, Bacterial Infections.
What interventions are being tested in trial NCT01702649?
The interventions under investigation include: Placebo (DRUG), RPX2003 (Biapenem) (DRUG).
Who is sponsoring clinical trial NCT01702649?
This trial is sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company), which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01702649 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
RECRUITING · Phase 1
-
Classroom Break, Cognition, and Fitness in Elementary School Children
RECRUITING · Phase 1
-
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.